A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance
about
Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?Role of the Drug Transporter ABCC3 in Breast Cancer ChemoresistanceRole of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.Salubrinal-Mediated Upregulation of eIF2α Phosphorylation Increases Doxorubicin Sensitivity in MCF-7/ADR Cells.E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer CellsAnticancer activity of salicin and fenofibrate.Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells.Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1.Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression.Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling.Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell LinesThe role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells.Co-delivery of hypoxia inducible factor-1α small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells.Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma.
P2860
Q26742115-D3CFDD52-FB36-43B4-83FC-EE62E21CF11BQ28552011-A6500850-95ED-437B-B99E-2C0C62CC06B9Q33719952-A444AED1-BFE0-4A39-AD91-85124D84E7C7Q36591295-D9EA271B-2933-4C40-9CBD-6F1FB8A9BA7EQ37716100-22557774-8FCE-4769-91A8-DB0F912050C7Q38696610-38BE0202-A05E-4EA3-9244-C1DF3B28716CQ38838744-72BC64C7-00EC-44FA-B4DD-E432DD0A14DAQ39782004-CD34E3F7-B34F-47E4-8A26-AB260A889F18Q41441070-D85A6EC6-1911-4372-A176-A58BA5C954D1Q41846145-B9295F6E-7FE1-40F6-9901-D930C4699662Q47100562-CC06F020-9627-4810-8AFE-1C64516BBF9EQ47245509-52DDABD6-3361-4664-84CD-1B6D14017BD7Q47769339-99DBADF7-6159-442B-BA1D-5EC51D8B6FBDQ48610668-03FA4722-F5E1-4E47-A860-D0DF79F7D720Q49679382-FEBC458D-32E9-4A18-A75D-D2DBEE2FAD5C
P2860
A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A critical dose of doxorubicin ...... acquiring multidrug resistance
@ast
A critical dose of doxorubicin ...... acquiring multidrug resistance
@en
A critical dose of doxorubicin ...... acquiring multidrug resistance
@nl
type
label
A critical dose of doxorubicin ...... acquiring multidrug resistance
@ast
A critical dose of doxorubicin ...... acquiring multidrug resistance
@en
A critical dose of doxorubicin ...... acquiring multidrug resistance
@nl
prefLabel
A critical dose of doxorubicin ...... acquiring multidrug resistance
@ast
A critical dose of doxorubicin ...... acquiring multidrug resistance
@en
A critical dose of doxorubicin ...... acquiring multidrug resistance
@nl
P2093
P2860
P3181
P1433
P1476
A critical dose of doxorubicin ...... acquiring multidrug resistance
@en
P2093
Hui-Ting Hsiao
Shang-Hsun Tsou
Tzer-Ming Chen
Yen-Hui Chen
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0116747
P407
P577
2015-01-01T00:00:00Z